Monte Rosa Therapeutics, Inc.GLUENASDAQ
Loading
Cash & Equivalents Over TimeContracting
Percentile Rank67
3Y CAGR+33.2%
5Y CAGR+25.5%
Studio
Year-over-Year Change

Cash on hand plus short-term liquid investments

3Y CAGR
+33.2%/yr
Annual compound
5Y CAGR
+25.5%/yr
Recent acceleration
Percentile
P67
Within normal range
vs 5Y Ago
3.1x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$129.88M-42.1%
2024$224.25M+75.1%
2023$128.10M+133.3%
2022$54.91M-84.1%
2021$346.07M+729.9%
2020$41.70M+595.6%
2019$6.00M-